Cost-effectiveness of TOMAC therapy for medication-refractory restless legs syndrome: an updated analysis based on Extension study data
The inclusion of longer follow-up data in the current analysis confirms earlier exploratory cost-effectiveness findings and suggest TOMAC therapy may provide a high-value treatment option for patients with medication-refractory RLS.
Authors
- Jan B. Pietzsch (ORCID: https://orcid.org/0000-0002-5078-1939)
- Anne M. Ryschon
- Asim Roy
Institutions
- Menlo School (US)
- Sleep Management Institute (US)
- SleepMed (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2024-09-28
- DOI
- https://doi.org/10.1080/13696998.2024.2410595
- Primary Topic
- Restless Legs Syndrome Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00